Treatments being tested
Clinical trials open to people with bowel cancer
Every trial here is a live record from ClinicalTrials.gov, the public registry every trial must be listed on before it starts. Statuses are re-checked against the registry every day or two, because a list that says a closed trial is recruiting is worse than no list at all.
Listing a trial is not a recommendation, and this site has no connection to any of them. Whether a trial is right for you, and whether you would be eligible, is a conversation for your own oncology team.
What these filters mean
Genotype
These are the things that make a tumour unusual, so leave them alone unless one of them is yours. Nothing selected shows every trial. Wild-type and pMMR are the ordinary results and have no button of their own: they would match almost everybody, so they would narrow nothing. Selecting a mutation drops the trials that need the ordinary result instead â which is right, because those are the ones you could not join.
Which KRAS
Only relevant if your tumour is KRAS mutated. Your report will name the exact change, such as G12C or G12D; some newer drugs are built for one specific change and no other.
Each trial is tagged by reading its own eligibility criteria automatically, to make the list searchable. The tags summarise what the criteria mention — they are not a decision about whether you qualify, and where a tag and the criteria disagree, the criteria are right.
145 trials
Recruiting nowPhase 1
AB122 Platform Study
Recruiting nowPhase 1
Study of RMC-5127 in Patients With Advanced KRAS G12V-Mutant Solid Tumors
Recruiting nowPhase 1
Study of ctDNA Guided Change in Tx for Refractory Minimal Residual Disease in Colon Adenocarcinomas
Recruiting nowPhase 1
A Study of STRO-004 in Adults With Refractory/Recurrent Metastatic Cancer
Recruiting nowPhase 1
IDOV-Immune for Advanced Solid Tumors
Recruiting nowPhase 1
Phase I Study of [177Lu]Lu-NNS309 in Patients With Pancreatic, Lung, Breast and Colorectal Cancers
Recruiting nowPhase 1
A Phase 1a/1b, First-Time-in-Human Study of CT-202, a Nectin-4 Directed Bispecific Antibody, in Participants With Recurring Triple Negative Breast, Colorectal, Urothelial Cancers
Recruiting nowPhase 1
A First-in-Human Study of HH160 in Participants With Advanced or Metastatic Solid Tumors
Recruiting nowPhase 1
Study to Assess Adverse Events and Pharmacokinetics in Adult Participants With Non-Small Cell Lung Cancer, Head and Neck Squamous Cell Carcinoma and Other Solid Tumors, Receiving Intravenous Infusion of Azirkitug Alone or in Combination(s) With Budigalimab, Bevacizumab, or Telisotuzumab Adizutecan
Recruiting nowPhase 1
A Study of LY4337713 in Participants With FAP-Positive Solid Tumors
Recruiting nowPhase 1
A Study of MRG007 (ARR-217) in Patients With Advanced Solid Tumors
Recruiting nowPhase 1
Study of Orally Administered MOMA-341 in Participants With Advanced or Metastatic Solid Tumors
Recruiting nowPhase 1
Open-Label Study of BBO-10203 in Subjects With Advanced Solid Tumors
Recruiting nowPhase 1
A Phase 1/1b Study of IAM1363 in HER2 Cancers
Recruiting nowPhase 1
Open-label Phase 1b Study of Ulixertinib and Cetuximab or Ulixertinib in Combination With Cetuximab and Encorafenib in Patients With Unresectable or Metastatic Colorectal Cancer Who Have Previously Received EGFR or BRAF-directed Therapy